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Introduction 
A case of hypersensitivity pneumonitis developing in a 
patient treated with cyclosporine for an exacerbation of 
Crohn’s colitis is reported. Cyclosporine is thought to be 
the causative agent, an observation that might have serious 
implications for those patients on cyclosporine therapy who 
develop diffuse bilateral infiltrates. 
Case History 
A 35-year-old white female was admitted to our hospital 
with fever, abdominal cramps, diarrhoea and weight loss. 
She had known Crohn’s colitis for 6 yrs which was treated 
with mesalazine. On admission, physical examination, lab- 
oratory tests of blood and stool, and coloscopy were all 
consistent with the diagnosis of an exacerbation of Crohn’s 
colitis. Systemic therapy with intravenous corticosteroids 
was initiated. After 4 weeks of treatment there was no 
improvement and cyclosporine, 4 mg kg ~ ’ of body weight 
day-‘, was added to the intravenous medication, under 
close monitoring of blood levels of cyclosporine. With this 
regimen, her condition improved and after 3 weeks, intra- 
venous medication was replaced by oral administration of 
both prednisolone, 30 mg day- ‘, and cyclosporine, 200 mg 
t.i.d., upon which patient’s condition continued to improve. 
However, 3 weeks after the start of oral therapy, the 
patient developed arthralgia of the knees and petechiae, 
with a mild thrombocytopenia of 85 000 ml ~ I, whereupon 
administration of cyclosporine was discontinued. The 
blood-cyclosporine level at this time was 244,ug 1 - ‘. 
In the subsequent days, the patient developed a fever up 
to 41°C and became progressively dyspnoeic. Chest X-ray 
revealed diffuse bilateral patchy reticula-nodular infiltrates 
with some basal alveolar consolidation. Blood gas analysis 
showed mark hypoxaemia (PO, 7.4 kPa, oxygen saturation 
89%). Laboratory tests revealed ESR 89 mm, CRP 
179 mg l- ’ and a white blood cell count of 4.3 x lo9 1 - ’ 
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with 79% neutrophilic granulocytes, 10% lymphocytes and 
2% eosinophilic granulocytes. 
Blood cultures were taken, which remained negative. A 
bronchoalveolar lavage (BAL) was performed. Toluidine 
blue, Giemsa, Gram and Ziehl-Neelsen stains were all 
negative. BAL fluid cell-differentiation showed 52% 
neutrophils, no eosinophils, 1% plasma cells and 37% 
lymphocytes with a CD4+/CD8+-ratio of 3.0. 
An open lung biopsy was performed through a limited 
incision leftsided thoracotomy. Material both for histology 
and cultures was taken. Cultures, specific cultures for 
Legionella, Mycoplasma and viruses included, both from 
lavage and open lung biopsy-specimens, remained negative, 
as did serological tests. Histological examination of the 
biopsies showed a diffuse thickening of the alveolar septa 
by oedema and an obvious infiltrate of both neutrophilic 
granulocytes, lymphocytes and some plasma cells, with a 
local more strongly broadened interstitium with a prolifer- 
ation of epithelial cells in vaguely circumscribed granuloma 
with sporadic multinucleated giant cells, an observation 
suggestive of an acute hypersensitivity pneumonitis. 
After surgery, the patient was transferred to the Intensive 
Care Unit and treatment with prednisolone, intensified to 
60 mg day- ‘, was continued. No specific therapy was 
started other than supplemental oxygen therapy, and no 
medication given prior to the febrile episode, i.e. mesala- 
zine, glibenclamide and prednisolone, was stopped. Within 
days the radiological abnormalities subsided and blood 
gases improved, and the patient was transferred to the ward 
where supplemental oxygen was soon stopped and pred- 
nisolone tapered. Within a week chest X-rays normalized as 
did blood gases at rest breathing room air. 
Lung function tests at this time showed a TLC of 85% of 
predicted, a FEV,/VC of 81% and a TLCO/VA of 76% 
of predicted. 
The colitis, for which, after resolution of the pneumo- 
nitis, azathioprine was started in combination with pred- 
nisolone, remained in remission. The patient was released 
from hospital 2 weeks after the thoracotomy, after a total 
hospital stay of 13 weeks. 
Discussion 
The case presented was diagnosed as an acute hypersensi- 
tivity pneumonitis, based upon the histological findings and 
the demonstration of plasma cells in the BAL fluid in 
CASE REPORTS 1369 
combination with both the absence of a demonstrable 
infectious cause and the spontaneous recovery without any 
specific antimicrobial therapy. In the case of a hypersensi- 
tivity pneumonitis one might have expected a different BAL 
fluid composition, i.e. a lymphocytic preponderance with a 
decreased CD4+/CD8+ ratio. However, neutrophilic pre- 
ponderance is known to occur early in acute hypersensi- 
tivity pneumonitis as described by Fournier et al. (1); and 
an elevated CD4 +/CDS + ratio has been observed by White 
et al. (2) in methotrexate-induced pneumonitis. Further- 
more, it may be speculated that the withdrawal of 
cyclosporine in our case might have caused a’ rise in the 
CD4+lCD8+ ratio, resulting in the slightly elevated ratio 
of 3.0 in our patient. 
Of course, alternative diagnoses were considered. In case 
of sarcoidosis, we would have expected more sharply cir- 
cumscribed granuloma in the biopsies and a more pro- 
nounced rise in the CD4+/CD8+ ratio: Drent et al. (3) 
found a mean ratio of 8.0 ( i 1.2) in non-smoking patients 
with histologically verified sarcoidosis with respiratory 
symptoms. Besides, in 401 cases of sarcoidosis Drent dis- 
covered plasma cells in BAL fluid in only five patients, of 
whom all were known to be frequently exposed to birds. In 
contrast, in patients with extrinsic allergic alveolitis and 
drug-induced pneumonitis, Drent found plasma cells in 
BAL fluid in 42.5% and 35.7% of cases, respectively (4) 
an observation that further strengthens our diagnosis of 
hypersensitivity pneumonitis. 
Furthermore, a direct correlation between the underlying 
inflammatory bowel disease in our patient and the inter- 
stitial lung disease was considered. The occurrence of inter- 
stitial lung disease in patients with inflammatory bowel 
disease however, is usually insidious, with biopsies showing 
changes similar to those found in interstitial pulmonary 
fibrosis. There is only one report of two patients with 
ulcerative colitis in whom widespread alveolitis developed 
rapidly and responded promptly and completely to admin- 
istration of prednisolone (5). Biopsies, however, showed 
interstitial infiltration and extensive cellular desquamation 
in one and interstitial fibrosis with chronic inflam- 
matory cells in the other, findings very distinct from the 
observations in our patient. 
Diagnosing our patient as an acute case of hypersensi- 
tivity pneumonitis, the one question that remained to be 
answered was the identification of the causative agent. Our 
patient used mesalazine (5-ASA), which is the active com- 
pound of sulfasalazine and lacks the component sulfapyri- 
dine which is held responsible for most of the side-effects 
known for sulfasalazine, including interstitial lung 
disease. In regard to mesalazine, however, there is one 
report in the literature (6) concerning a case of bilateral 
interstitial infiltrates developing gradually in a patient 
on 5-ASA over a period of 2 years, with definite improve- 
ment within months after the discontinuation of the 
drug, a clinical course, very unlike our case. In our 
patient, mesalazine was continued during the entire 
course of events, practically excluding it as a possible 
cause of hypersensitivity in our patient, a statement that 
also applies to the other medication used by our patient, 
glibenclamide. 
Since only the administration of cyclosporine was ceased, 
this drug was thought to be the probable causative agent, 
an observation neither mentioned before in major reports 
on drug-induced pulmonary disease (7-11) nor in the 
literature referring to cyclosporine-associated toxicity. 
Proof for this diagnosis could have been obtained by 
rechallenging the patient to cyclosporine, but this was 
considered unacceptable in view of the possible hazardous 
effect and the small benefit that could be expected of 
renewed cyclosporine administration, as the colitis was 
already in remission and the indication for cyclosporine was 
not uncontroversial, as stated in recent literature (12-15). 
In conclusion, cyclosporine was identified as the probable 
cause of an acute hypersensitivity pneumonitis in our 
patient, on observation that might have serious implica- 
tions for those patients treated with cyclosporine, e.g. after 
organ transplantation, in whom diffuse pulmonary 
infiltrates may develop without an infectious cause. 
Withholding further cyclosporine therapy could then 
be considered as a possible treatment, preferably after 
obtaining histology. 
We believe that cyclosporine should be added to the 
extensive list of pharmacological substances responsible for 
drug-induced lung disease. 
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Introduction 
Gaucher disease (GD) is a rare condition caused by an 
inherited, autosomal recessive deficiency of the enzyme 
P-glucocerebrosidase, resulting in an accumulation of 
glucocerebroside in the lysosomes of macrophages and 
monocytes. Three distinct clinical forms are recognized. 
Type 1 (chronic non-neuropathic or ‘adult form’) is 
the most common, and its onset can occur at any age. 
This form is most frequent among Ashkenazy Jews, 
although any race can be affected. It is characterized by 
hepatosplenomegaly, thrombocytopenia and bone lesions, 
and lung involvement is rare (1). Type 2 (acute neuropathic) 
is characterized by severe visceral involvement and an 
intense and early neurological affection, with spasticity, 
bulbar signs and oculomotor palsy, and a fatal outcome 
within the first 2 years of life. Type 3 (subacute neuro- 
pathic) has a clinical pattern intermediate between types 1 
and 2. We report our results of enzyme replacement therapy 
(ERT) with alglucerase in a patient suffering from type 1 
GD with pulmonary interstitial involvement and severe 
pulmonary hypertension (PHT). 
Case Report 
A 29-year-old Caucasian, not Jewish, woman was first 
diagnosed with Gaucher disease at the age of 9 years, 
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with a clinical picture consisting of a 7-cm hepatomegaly 
and a 12-cm splenomegaly, pancytopenia and bone 
lesions, and after observation of characteristic Gaucher 
disease cells in a bone marrow biopsy and detection of 
enzyme deficiency in peripheral leukocytes (6% of control 
value). DNA analysis showed a N370S/D55 geno- 
type. Thrombocytopenia (platelet counts: 21 000 ,u- ‘), 
anaemia (haemoglobin: 8.1 g dl ~ ‘) and haemorrhagic 
manifestations increased subsequently, and a splenectomy 
was performed at age 19 years, with a subsequent 
correction in blood counts. 
From 1993 (at the age of 24 years), she began to suffer 
from progressive exertional dyspnoea and impaired 
pulmonary function tests, with a reduction of carbon 
monoxide diffusing capacity (DLCO) (Table 1). Chest 
FIG. 1. Chest radiograph showing enlargement of 
pulmonary arteries. 
